Liu-Chittenden et al. found that verteporfin (VP) could bind to YAP and thereby disrupt its interaction with TEAD.373 In subsequent studies, VP was widely used to treat various diseases, including cancers,374–378 fibrotic diseases379,380 and glaucoma.381 Moreover, as a recognized YAP-TEAD interaction or YAP inhibitor, VP has been frequently used in studies of Hippo-related mechanisms.382,383 However, similar to other potential Hippo-targeted small molecule inhibitors, VP was shown to have off-target and YAP-independent toxic effects.384. The gene discussed is YAP1; the disease is glaucoma.